Where Pactiv Evergreen Stands With Analysts
Analysts have provided the following ratings for Pactiv Evergreen (NASDAQ:PTVE) within the last quarter:
Goldman Sachs Maintains Neutral Rating for Pactiv Evergreen: Here’s What You Need To Know
Goldman Sachs has decided to maintain its Neutral rating of Pactiv Evergreen (NASDAQ:PTVE) and lower its price target from $12.00 to $10.50.
Shares of Pactiv Evergreen are trading down 1.55% over the last 24 hours, at $9.51 per share.
Citigroup Maintains Neutral on Pactiv Evergreen, Lowers Price Target to $9
Citigroup analyst Anthony Pettinari maintains Pactiv Evergreen (NASDAQ:PTVE) with a Neutral and lowers the price target from $12 to $9.
Recap: Pactiv Evergreen Q2 Earnings
Pactiv Evergreen (NASDAQ:PTVE) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Pactiv Evergreen beat estimated earnings by 100.0%, reporting an EPS of $0.4 versus an estimate of $0.2.
Tired Of DoorDash Drivers Stealing Your Fries? This Company Provides A Fix
Circuit Route Planner is a route optimization app targeted toward delivery drivers who work for companies such as UberEats, part of Uber Technologies Inc (NYSE: UBER), DoorDash Inc (NYSE:
Pactiv Evergreen Introduces Tamper Evident Fry Cartons
Pactiv Evergreen Inc (NASDAQ:PTVE) has launched new Tamper Evident Fry Cartons to meet the evolving needs of foodservice operators. Tamper Evident…
RBC Capital Upgrades Pactiv Evergreen to Outperform, Raises Price Target to $13
RBC Capital analyst Arun Viswanathan upgrades Pactiv Evergreen (NASDAQ:PTVE) from Sector Perform to Outperform and raises the price target from $9 to $13.
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
BofA Downgrades Pactiv Evergreen, O-I Glass – Read Why
BofA analyst George Staphos downgraded Pactiv Evergreen Inc (NASDAQ:PTVE) to Neutral from Buy with a price target of $13 (29.6% upside). The analyst…
